This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.
There is a significant need for quality-improvement initiatives in initial breast cancer care, as well as prominent geospatial variation in receipt of that care, which remains unexplained, according to a new study that investigated care delivery among patients with stage I to III disease.
Findings were published online today in JAMA Oncology.
This analysis, which was conducted using data from 31,571 (mean [SD] age, 71 [68-75] years) patients, investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis (proxy for screening mammography and timely surgery), chemotherapy receipt, radiation therapy receipt, endocrine therapy (ET) initiation (within a year of diagnosis), and endocrine therapy continuation (3-5 years after diagnosis). The survey was conducted from January 1, 2007, through December 31, 2016, and data analyzed between January and June 2021.
“For each metric, total variance was attributed proportionally to 4 domains—random, patient factors (eg, age, race and ethnicity, socioeconomic status), region (health service area [HSA]), and unexplained—using hierarchical multivariable modeling,” the authors explained.
The retrospective population-based cohort study gleaned its data from the Surveillance, Epidemiology, and End Results–Medicare database for patients who received a diagnosis from 2007 through 2013, and the primary goal was to get a clear view of the extent of geospatial variation in breast cancer care.
Among the 5 metrics evaluated, patient factors likely had the least influence on variation in breast cancer care, at 1% to 4%, while region/HSA appeared to have the most influence, at 24% to 48%. In addition, for region/HSA variance, the blame may lie with ET initiation (28%) and ET continuation (39%). Most patients received radiation (81.6%), received chemotherapy (72.8%), initiated ET (48.8%), or continued ET (52.1%).
Still, 35% to 54% of care variation remained unexplained, the investigators highlighted.
Despite county-level data showing wide swings in breast cancer–related mortality—from 11.2 to 51.6 deaths per 100,000 women—and certain patient populations proving to be at higher risk of death from the disease—Black individuals, low-income people, older adults, and patients living in rural areas—the authors noted there is a lack of research on the impact of geographic factors on disease outcomes. Two important questions remain unanswered, they said:
In fact, in this study, most participants were non-Hispanic White vs Black (83.7% vs 6.1%), lived in an all-urban vs an all-rural area (60.2% vs 8.0%), were aged 70 to 74 years vs 75 to 79 years (39.3% vs 26.6%), and had no comorbidities vs having 2 or more (64.1% vs 13.4%). These numbers were seen despite fewer instances of stage I disease and receipt of treatment among patients of an older age, with multiple comorbidities, and who are Black. Especially among Black patients, ET use is much less, the authors noted.
In fact, "the ET metrics demonstrated the largest total observed variance, the lowest absolute performance, and the strongest association with region/HSA,” the authors concluded. “This is remarkable, considering that ET confers an impressive one-third reduction in the risk of death from breast cancer in the first 15 years after diagnosis.”
Next steps, they said, should focus on the portion of geospatial variation that remains unexplained, especially where doing so can help to optimize the delivery of ET.
Reference
Hassett MJ, Tramontano AC, Uno H, Ritzwoller DP, and Punglia RS. Geospatial disparities in the treatment of curable breast cancer across the US. JAMA Oncol. Published online January 27, 2022. doi:10.1001/jamaoncol.2021.7337
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More